Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 27

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not recruiting

Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen - Cilag International

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen - Cilag International

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acromegaly

Not recruiting

Study of long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Hydrochloride
  • Sponsor:Camurus AB

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Active Psoriatic Arthritis in Patients with Inadequate Response to One Prior Anti-TNF Agent

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Short stature

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.